Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Foradil Completes LABAs’ Exit From Risk Evaluation and Mitigation Strategies

Executive Summary

FDA says Novartis’ assessment of the long-acting beta agonist’s REMS, which consisted only of a communication plan, shows the “plan, and therefore the REMS, has met its goal.”


Related Content

FDA Supersizes Its Order For LABA Safety Studies
MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy
LABA Label Changes Could Reinvigorate Single-Ingredient Products
LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
FDA Outreach To Physicians On LABAs Shows Challenges Of Safety Strategy
FDA Calls For Class-Wide REMS For LABA Asthma Drugs
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts